A study published in Neurology Clinical Practice suggested that acid-reducing drug users, including those on proton pump inhibitors, H2 blockers, and antacid supplements, face increased migraine risk. Proton pump inhibitor users had a 70% higher risk, H2 blocker users had a 40% higher risk, and antacid supplement users had a 30% higher risk.